Loading viewer...
investor_presentation
Format: PDF investor_presentation
Q2 FY20/21 investor presentation covering Samtrans' financial performance with improved earnings driven by retroactive compensation and strong operational results. Net sales reached SEK 2,564 million with adjusted EBT of SEK 153 million, reflecting cost control improvements and positive contract migration effects despite Covid-19 headwinds.
II-VI Incorporated
Iovance Biotherapeutics Investor Presentation — August 2024
investor_presentationinvestor_presentation
34 Pages
Iovance Biotherapeutics, Inc